Clinical Trials Browser

Non-Small Cell Lung Cancer ALK-positive × lorlatinib × 90 days × Clear all

NCT07556549 2026-05-22

A Study to Learn About Study Medicine Lorlatinib, as a First-line Treatment in Chinese Adults With ALK-positive a/mNSCLC

Active not recruiting

Non-Small Cell Lung Cancer ALK-positive